Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Priority to CR7318ApriorityCriticalpatent/CR7318A/en
Publication of CR7318ApublicationCriticalpatent/CR7318A/en
Se describen nuevas formas anhidras cristalinas de gabapentina formadas a partir de gabapentina monohidrato. Las nuevas formas cristalinas ofrecen ventajas para la elaboracion del agente terapeutico.New crystalline anhydrous forms of gabapentin formed from gabapentin monohydrate are described. The new crystalline forms offer advantages for the elaboration of the therapeutic agent.
CR7318A2004-04-012004-04-01
NEW ANHYDRA CRYSTAL SHAPES OF LA GABAPENTINA
CR7318A
(en)
Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound.